Aldeyra Therapeutics (ALDX) Market Capitalization (2014 - 2026)

Aldeyra Therapeutics (ALDX) has reported Market Capitalization for 13 consecutive years, with $128.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Market Capitalization fell 44.13% year-over-year to $128.5 million; the trailing twelve-month figure through Jun 2026 stood at $128.5 million (down 44.13% YoY), and the FY2025 full-year result was $311.6 million, up 4.7% from the prior year.
• Market Capitalization improved to $128.5 million in Q2 2026 per ALDX's latest filing, from $101.9 million in the prior quarter.
• Across five years, Market Capitalization topped out at $583.8 million in Q1 2023 and bottomed at $101.9 million in Q1 2026.
• Historically, Market Capitalization has averaged $296.3 million across 5 years, with a median of $304.6 million in 2024.
• The sharpest annual moves came in 2023 and 2026: Market Capitalization soared 125.28% in 2023, then slumped 70.47% in 2026.
• Over 5 years, Market Capitalization stood at $407.6 million in 2022, then tumbled by 49.02% to $207.8 million in 2023, then jumped by 43.25% to $297.6 million in 2024, then climbed by 4.7% to $311.6 million in 2025, then tumbled by 58.77% to $128.5 million in 2026.
• According to Business Quant data, Market Capitalization over the past three periods registered $128.5 million, $101.9 million, and $311.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.